Sorry if I missed it, but are you generally more optimistic on what BMY aims to do in collaboration with QURE on the gene therapy cardio front or are you as skeptical on that approach as you are with what CLDN is doing?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.